Journal
NATURE BIOTECHNOLOGY
Volume 32, Issue 9, Pages 941-946Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.2951
Keywords
-
Categories
Funding
- National Institutes of Health [P01 CA108631]
- Leukemia and Lymphoma Society Scholar Award
- SPARC consortium
- National Human Genome Research Institute [5P50HG006193-02]
- Klarman Family Foundation at The Broad Institute
- German Cancer Foundation
Ask authors/readers for more resources
Genome sequencing studies have shown that human malignancies often bear mutations in four or more driver genes(1), but it is difficult to recapitulate this degree of genetic complexity in mouse models using conventional breeding. Here we use the CRISPR-Cas9 system of genome editing(2-4) to overcome this limitation. By delivering combinations of small guide RNAs (sgRNAs) and Cas9 with a lentiviral vector, we modified up to five genes in a single mouse hematopoietic stem cell (HSC), leading to clonal outgrowth and myeloid malignancy. We thereby generated models of acute myeloid leukemia (AML) with cooperating mutations in genes encoding epigenetic modifiers, transcription factors and mediators of cytokine signaling, recapitulating the combinations of mutations observed in patients. Our results suggest that lentivirus-delivered sgRNA:Cas9 genome editing should be useful to engineer a broad array of in vivo cancer models that better reflect the complexity of human disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available